BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35038703)

  • 1. MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene.
    Molony P; Smith AC; Selvarajah S; Sakhdari A
    Cytogenet Genome Res; 2021; 161(12):564-568. PubMed ID: 35038703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a t(X;17)(q28;q21) generating a KANSL1-MTCP1 gene fusion leading to dysregulated expression of MTCP1 in acute myeloid leukemia.
    Li SX; Chen XJ; Jiang L; Lei YC; Zhang YX; Dai B; Zhang WN; Zhong ML; Fan YL; Chen QS; Liu H; Huang JY; Chen B
    Genes Chromosomes Cancer; 2020 Jul; 59(7):417-421. PubMed ID: 32167630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
    Shallis RM; Zeidan AM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
    Li Y; Beck RC; Moore EM
    Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.
    Behnert A; Lee AG; Young EP; Breese MR; Leung SG; Behroozfard I; Maruffi M; Sweet-Cordero EA; Dvorak CC; Chu J; Stieglitz E
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):e808-e811. PubMed ID: 32815876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
    Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
    Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report.
    Hoshino Y; Manaka K; Sato J; Asatsuma Y; Horikoshi H; Takeuchi M; Ito N; Fujita M; Yasunaga M; Matsuda K; Honda A; Maki H; Masamoto Y; Kurokawa M; Nangaku M; Makita N
    BMC Endocr Disord; 2023 Jun; 23(1):128. PubMed ID: 37277771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.
    Ismael O; Shimada A; Hama A; Elshazley M; Muramatsu H; Goto A; Sakaguchi H; Tanaka M; Takahashi Y; Yinyan X; Fukuda M; Miyajima Y; Yamashita Y; Horibe K; Hanada R; Ito M; Kojima S
    Br J Haematol; 2012 Jul; 158(1):129-37. PubMed ID: 22571758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
    Thota S; Gerds AT
    Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
    Wan Z; Han B
    Front Oncol; 2020; 10():579221. PubMed ID: 33117717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.
    Wang Q; Dai HP; Liu DD; Xie JD; Yao H; Ding ZX; Tao TT; Chen SN; Zhang R
    Leuk Res Rep; 2020; 14():100229. PubMed ID: 33194542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.